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Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugala; Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugalb;
Centro de Investigação em Química, Universidade do Porto, Porto, Portugalc; Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto,
Porto, Portugald; and iMed.UL, CECF, Faculdade de Farmácia, Universidade de Lisboa, Lisbon, Portugale
The current treatment of visceral leishmaniasis is made difficult by the low efficacy, elevated costs, low bioavailability, and high
toxicity of many of the available drugs. Primaquine, an antimalarial 8-aminoquinoline, displays activity against Leishmania spp.,
and several of its derivatives have been developed as potential antileishmanial drugs. However, primaquine exhibits low oral
bioavailability due to oxidative deamination of its aliphatic chain. We previously developed peptidomimetic and organometallic
derivatives of primaquine, with higher resistance to proteolytic degradation and oxidative deamination, which presented signifi-
cant activity against primaquine-sensitive pathogens such as Plasmodium or Pneumocystis. In light of these relevant findings, we
decided to evaluate these compounds against both the promastigote and intramacrophagic amastigote forms of Leishmania in-
fantum, the agent of Mediterranean visceral leishmaniasis. We found that several of these compounds had significant activity
against L. infantum. One of the peptidomimetic (3c) and one of the organometallic (7a) derivatives of primaquine were active
against the clinically relevant intramacrophagic amastigote form of the parasite, causing>96% reductions in the number of
amastigotes per 100 macrophages at 60 and 40M, respectively, while being less cytotoxic for host cells than the reference drugs
sitamaquine andmiltefosine. Hence, compounds 3c and 7a represent new entries toward the development of new antileishma-
nial leads.
Leishmania species are digenetic protozoa that alternate be-tween motile promastigotes in the gut of the sand fly and non-
motile amastigotes inside macrophage phagolysosomes of the
mammalian host. These parasites are the causative agents of leish-
maniasis, a disease with clinical symptoms that range in severity
from self-healing cutaneous lesions to serious mucocutaneous
disfigurement and fatal visceralizing infection. TheWorld Health
Organization estimates that more than 12 million people are cur-
rently infected, with 2 million new cases occurring every year and
350 million people, in 98 different countries, at risk of acquiring
the infection (43).
Visceral leishmaniasis (VL) is the most severe form of the dis-
ease, being fatal if left untreated, with an annual incidence esti-
mated at 0.5 million cases, causing around 50,000 deaths annually
(a rate exceeded only by malaria among protozoan diseases) (43).
VL is caused by Leishmania donovani in East Africa and the Indian
subcontinent and by L. infantum in Europe, North Africa, and
Latin America. Active VL is characterized by weight loss, fever,
weakness, and hepatosplenomegaly, among other symptoms (23).
The increasing number of HIV-Leishmania coinfections has
raised the incidence of the disease, reduced the likelihood of a
therapeutic response, and greatly contributed to the probability of
relapse (1).
Since there are currently no effective vaccines to prevent Leish-
mania infections,management of VL relies on chemotherapywith
first-line drugs, i.e., pentavalent antimonials (sodium stiboglu-
conate and meglumine antimoniate), and second-line drugs, i.e.,
pentamidine, paromomycin, amphotericin B or its lipid formula-
tions, and miltefosine (5). However, these drugs present several
problems, such as specific toxicities, elevated costs, prolonged
treatment regimens, low patient compliance, and parasite resis-
tance (18). Therefore, alternative drugs and combination regi-
menswith improved therapeutic effectiveness are urgently needed
to treat VL (41).
8-Aminoquinolines (8AQ) have been established as a promis-
ing class of drugs for the oral treatment of malaria, Pneumocystis
jirovecii pneumonia, leishmaniasis, and trypanosomiasis (35, 40).
Primaquine (PQ) (compound 1 in Fig. 1), an antimalarial 8AQ, is
known to exhibit activity against visceral leishmaniasis (3, 12, 13,
15, 25, 29). Since it leads to some adverse side effects and has a
lower therapeutic index than those of VL reference drugs, PQ
currently has no applicability in the VL clinical setting. The opti-
mization of the PQ structure has already led to the discovery of
three promising 8AQ:NPC1161B (24), tafenoquine (44), and sita-
maquine (24, 25), which demonstrated high activity against ex-
perimental VL. Sitamaquine has completed phase IIb clinical trials
by GlaxoSmithKline, although it has shown variable results and
unexpected cases of toxicity (10, 14, 34, 42).
Interestingly, earlier works suggested that PQ encapsulation in
liposomes or nanoparticles enhances its leishmanicidal activity
either in infected macrophages (29) or in animal models of infec-
tion (3, 29). This enhanced effect may be due to the fact that
encapsulation of PQ prevents it from undergoing metabolic inac-
tivation to carboxyprimaquine (compound 2 in Fig. 1) (39), thus
increasing the drug’s bioavailability. Therefore, it is reasonable to
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expect that alternative strategies that prevent PQ conversion into
its inactive metabolite, compound 2, will possibly contribute to
improvement of the drug’s activity against VL.
We have been working on the synthesis and biological evalua-
tion of PQ derivatives in which the aliphatic amine of the parent
drug has been masked by acylation with a peptidomimetic (com-
pound 3) (Fig. 1) or organometallic (compounds 5 to 10) (Fig. 2)
moiety as a strategy to (i) avoid premature oxidative deamination
of PQ to compound 2 and (ii) confer resistance to proteolytic
degradation, which affects PQ dipeptide derivatives such as com-
FIG 1 Chemical structures of primaquine (1), its main metabolite, carboxyprimaquine (2), and its peptidomimetic (3a-e) and dipeptidic (4a-i) derivatives. Cyt
P450, cytochrome P450; MAO, monoamine oxidase.
FIG 2 Chemical structures of primaquine’s organometallic derivatives 5 to 10.
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pound 4 (Fig. 1) (2, 26, 38, 40). Compounds 3 and 5 to 10 have
previously revealed remarkable activity against PQ-sensitive
pathogens, namely, Plasmodium (malaria) and Pneumocystis
(pneumocystic pneumonia), in some cases with better perfor-
mances than that of PQ at the activity and/or toxicity level (19, 20,
36, 40). In view of this and the known antileishmanial properties
of 8AQ analogues of PQ, such as sitamaquine, the present work
aimed to explore the activity of the peptidomimetic and organo-
metallic PQ derivatives against L. infantum, the causative agent of
Mediterranean VL. As presented here, some of these compounds
exhibited antileishmanial activity which was stronger than that of
PQ and comparable to that of the reference antileishmanial drugs
sitamaquine andmiltefosine, while having lower cytotoxicity than
the latter. These findings emphasize the importance of scrutiniz-
ing the activity of PQ derivatives or analogues against protozoan
pathogens other than Plasmodium.
MATERIALS AND METHODS
Chemical synthesis. Synthetic procedures and structural data have been
reported elsewhere for compounds 3a to e (40) and 4b (38). Other com-
pounds of the PQ-Pro-Xaa series, i.e., 4a and c to i, were synthesized as
previously described for compound 4b (38), and spectroscopic data as
well as high-pressure liquid chromatography (HPLC) traces are available
upon request. Synthetic procedures and chromatographic/spectroscopic
data were reported elsewhere for compounds 5 to 10 (19, 20), except for
compound 7h, for which relevant procedures and data are available upon
request.
Reagents. Sitamaquine was supplied by GlaxoSmithKline (Brentford,
Middlesex, United Kingdom). Miltefosine was purchased from Cayman
Chemical (Ann Arbor, MI). All compounds used in this study were dis-
solved in dimethyl sulfoxide (DMSO) and stored at20°C.
Parasites. Promastigotes of the L. infantum strain MHOM/MA/67/
ITMAP-263 were differentiated at 25°C in complete Schneider’s medium
(Sigma-Aldrich Co., St. Louis, MO) supplemented with 20% heat-inacti-
vated fetal bovine serum (FBS), 100Uml1 penicillin, 100gml1 strep-
tomycin (all from Gibco, Life Technologies, Carlsbad, CA), 2% human
urine, 5 g ml1 phenol red (Sigma), and 5 mM HEPES sodium salt
(Sigma), pH 7.4, from amastigotes present in the spleens of infectedmice.
Promastigote cultures were expanded at 25°C, for a maximum of 5 pas-
sages, in RPMI 1640 GlutaMAX-I medium (Gibco, Life Technologies)
containing 20% FBS, 50 Uml1 penicillin, 50gml1 streptomycin, and
25mMHEPES sodium salt, pH 7.4. Promastigote differentiation from the
exponential to the stationary phase was promoted by culture at 25°C,
without medium renovation, for 4 to 5 days.
Drug screening assay on promastigotes. Promastigotes (1  106/
well) were cultured at 25°C in complete RPMI medium supplemented
with the various compounds at concentrations between 2.5 and 160 M
(200-l total volume). After 24 h of culture, 20 l of a 2.5 mM resazurin
solution (freshly prepared and filtered in phosphate-buffered saline, pH
7.4 [Sigma]) was added to each well. The fluorescence intensity, corre-
sponding to resazurin conversion to the fluorescent compound resorufin,
was determined 48 h after resazurin addition (excitation wavelength of
560 nm and emission wavelength of 590 nm on a SpectraMAXGeminiXS
fluorometer [Molecular Devices LLC, Sunnyvale, CA]). All experimental
conditions were carried out in triplicate. The 50% inhibitory concentra-
tion (IC50) (M) values were determined with GraphPad Prism 5.0 soft-
ware (GraphPad Software Inc., La Jolla, CA) from plots of percentages of
parasite growth in relation to control versus inhibitor concentrations.
Bone marrow-derived macrophages. Macrophages were derived
from the bonemarrow of BALB/cmice as follows. Each femurwas flushed
with 5 ml of Hanks’ balanced salt solution (HBSS; Gibco). The resulting
cell suspension was centrifuged and the cells resuspended in complete
Dulbecco’s modified Eagle’s medium (DMEM; Gibco) containing 10%
FBS, 2mM L-glutamine, 1mM sodium pyruvate, 50 Uml1 penicillin, 50
g ml1 streptomycin, 10 mM HEPES, pH 7.4, and 10% L929 cell-con-
ditionedmedium (LCCM), as a source ofmacrophage colony-stimulating
factor (M-CSF). The cells were distributed in 24- or 96-well plates with or
without sterile and lipopolysaccharide (LPS)-free microscopy slides and
were incubated at 37°C in a 7%CO2 atmosphere. Three days after seeding,
100 l of LCCM was added. On the 7th day of culture, the medium was
renewed.
Infection of bonemarrow-derivedmacrophages.On the 10th day of
culture, completely differentiated macrophages adhered to microscope
slides (4 105 macrophages/well) were infected with stationary promas-
tigotes of L. infantum at an approximate macrophage/parasite ratio of
1:10. After 4 h at 37°C in a 7% CO2 atmosphere, cells were washed with
warmHBSS to remove noninternalized promastigotes and reincubated in
complete DMEM. Compounds were added to the desired concentrations
after 24 h of culture. Cells were fixed and stained with Hemacolor (Merck
KGaA, Darmstadt, Germany) 24 or 72 h later. The slides were visually
inspected under a light microscope to determine the number of parasites
present inside macrophages. The “parasite index” was calculated as the
number of amastigotes per 100 macrophages. Each experimental condi-
tion was tested in triplicate wells. A minimum of 400 macrophages was
counted per slide. Representative pictures of stained cells were obtained
with an Olympus CX31 light microscope equipped with a DP-25 camera
(CellB imaging software; Olympus, Center Valley, PA), at amagnification
of400.
Drug cytotoxicity assay on bonemarrow-derivedmacrophages.On
the 10th day of culture, macrophages (8 104/well) were treated with the
various compounds at the desired concentrations (200-l total volume).
Twenty-four or 72 h later, 20 l of a 1.25 mM resazurin solution was
added to each well, and the plates were reincubated at 37°C for another 3
h. The fluorescence intensity was determined as described above. All ex-
perimental conditions were carried out in triplicate. The 50% cytotoxic
concentration (CC50) (M) values were determined with GraphPad
Prism 5.0 software (GraphPad Software Inc., La Jolla, CA) from plots of
percentages of viability in relation to control relative to inhibitor concen-
trations.
Statistical analysis.One-way analysis of variance (ANOVA) followed
by Bonferroni’s multiple-comparison post hoc test was performed to de-
termine the statistical significance of differences between groups treated
with vehicle and groups treated with the different compounds.
RESULTS
In vitro activity against L. infantum promastigotes. Our first
approach was to test PQ and its peptidomimetic, dipeptidic, and
organometallic derivatives on axenic cultures of L. infantum pro-
mastigotes. The promastigote stage of Leishmania is best suited to
this purpose due to its simplicity of cultivation, allowing a fast and
easy way to screen a large number of drugs.
Results obtained for compounds of the 3 and 4 series (Fig. 1)
are depicted in Table 1. Two of these compounds, 3c and 4c, were
as active as PQ (compound 1) against L. infantum promastigotes,
whereas all other derivatives from these series displayed lower or
no activity. Although compounds 3c and 4c are among the PQ
derivatives with the highest lipophilicity values (clogP values)
(compound 3c ranks 1st), there was no direct correlation between
clogP values and IC50s (Table 1). This is clearly shown by the
significantly different IC50s obtained with compounds 4d to 4f,
whose calculated clogP values are identical. It is interesting,
though, that -ramification of the amino acid (Xaa) residue may
have a role in antimicrobial activity, as all PQ derivatives which
displayed IC50s of35 M bore a -ramified Xaa residue. Other
structural features in Xaa, such as the presence/absence of ioniz-
able (as in compound 4h) or hydrogen-bonding (as in compound
4g or 4h) groups, as well as the bulkiness of the hydrocarbon
Vale-Costa et al.
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amino acid side chains in subsets 3a to c and 4a to f (expressed by
Charton’s steric factor  [6] [Table 1]), did not seem to have any
particular effect on a compound’s activity against L. infantum.
Since several reports indicate that iron potentiates the leish-
manicidal activity of several drugs (21, 33), and since we have
previously shown that ferrocene (Fc) derivatives of PQ are ac-
tive against Plasmodium (19) and Pneumocystis (20), we next
tested a series of Fc derivatives of PQ for activity against L.
infantum promastigotes. The results obtained with compounds
5 to 10 (Fig. 2) are shown in Table 2. The compounds of series
7, in which PQ is linked to Fc through a variable amino acid
spacer, were generally inactive or performed worse than PQ
and the reference drugs sitamaquine (compound 11) and
miltefosine (compound 12) (Fig. 3). Relevantly, removal of the
amino acid spacer between PQ and Fc, giving compound 5, led
TABLE 1 Antiparasitic activities and macrophage toxicities of primaquine (1), its peptidomimetic (3a to e) and dipeptidic (4a to i) derivatives, and
the reference drugs sitamaquine (11) and miltefosine (12), with estimated clogP values and Charton’s steric parameter () values for relevant
hydrocarbon amino acid side chains
Compound R1a R2a R3a
IC50 (M) on L. infantum
promastigotes at 72 h
(mean SD)
CC50 (M) on mouse bone
marrow-derived macrophages at
24 h (mean)
clogP
valueb
 (for R2
or R3)c
1 32.2 1.0 60 2.04
3a H H 74.8 1.7 1.82 0
3b H Me 64.4 1.2 2.22 0.52
3ce H iPr 31.8 1.0 60 3.03 0.76
3d H (CH2)2SMe 80 2.40
3e Me H 80 2.10
4a H 80 1.05 0
4b Me 80 1.45 0.52
4ce iPr 31.6 1.0 60 2.25 0.76
4d sBu 37.6 1.0 2.72 1.02
4e iBu 80 2.72 0.98
4f Bzl 52.0 1.4 2.72 0.70
4g p-(OH)Bzl 80 2.43
4h (CH2)4NH2 62.9 1.5 1.35
4i (CH2)2SMe 43.3 1.0 1.62
11 7.4 1.0 60 5.84d
12 14.4 1.1 60 3.30
a R stands for the amino acid side chain. H, hydrogen; Me, methyl; iPr, isopropyl; iBu, isobutyl; sBu, sec-butyl; Bzl, benzyl.
b Calculated using the OSIRIS Property Explorer (http://www.organic-chemistry.org/prog/peo/).
c Taken from reference 6.
d Experimental value taken from reference 16.
e -Ramified amino acid.
TABLE 2 Antiparasitic activities and macrophage toxicities of
primaquine (1), its organometallic derivatives 5 to 10, and the reference
drugs sitamaquine (11) and miltefosine (12)
Compound Ra
IC50 (M) on
L. infantum
promastigotes
at 72 h (mean
 SD)
CC50 (M) on mouse
bone marrow-derived
macrophages at 72 h
(mean SD)
1 26.5 1.2 80
5 22.7 1.1 80
6 4.9 2.3 6.8 1.2
7a H 80 80
7b Me 44.7 1.1
7cb iPr 80
7d iBu 80
7e Bzl 80
7f (CH2)4NH2 40.3 2.5
7g CH2NH2 39.2 6.2
7h CH(CH3)OH 63.3 1.3
8 11.5 1.0 80
9 80
10 80
11 7.4 1.0
12 14.4 1.1 24.7 0.5
a R stands for the amino acid side chain. H, hydrogen; Me, methyl; iPr, isopropyl; iBu,
isobutyl; Bzl, benzyl.
b -Ramified amino acid. FIG 3 Chemical structures of sitamaquine (11) and miltefosine (12).
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to an increase in activity, which became higher than that of PQ
but lower than those of the reference drugs sitamaquine (com-
pound 11) and miltefosine (compound 12). Compounds 9 and
10 were inactive, although the latter had shown the highest
activity against Plasmodium (19). Compound 10 was obtained
by directly binding a hexylferrocene moiety to the PQ het-
eroaromatic core, 8-amino-6-methoxyquinoline. Interest-
ingly, inserting the same hexylferrocene moiety of compound
10 into PQ itself led to compound 6, which exhibited a remark-
ably higher activity against promastigotes and was more potent
than both reference drugs (compounds 11 and 12). Finally,
compound 8, whose structure encompasses an imidazolidin-4-
one and an Fcmoiety, also showed significant activity against L.
infantum promastigotes, comparable to that of miltefosine
(compound 12). With the exception of compound 6, no other
PQ derivative ranked higher than sitamaquine (compound 11).
Nonetheless, toxicity issues with this drug, the fact that pep-
tidomimetic derivatives of PQ are promising alternatives to PQ
due to enhanced chemical and metabolic resistance (37, 40),
and the good activities demonstrated by the organometallic
series of compounds motivated us to further explore the po-
tential of some of them against the amastigote form of Leish-
mania parasites.
In vitro activity against intramacrophagic L. infantum amas-
tigotes. In light of the observations made in the previous section,
compounds 3c and 4c (Fig. 1), as well as compounds 5 and 8 (Fig.
2), were selected for evaluation on intramacrophagic L. infantum
amastigotes, the clinically relevant parasite stage. The high toxicity
of compound 6 toward mouse bone marrow-derived macro-
phages (Table 2) excluded it from further testing. Compound 7a
was included in these studies for comparison with compound 8,
for which it is the synthetic acyclic precursor. Moreover, PQ
(compound 1), sitamaquine (compound 11), and miltefosine
(compound 12) were included as reference drugs.
The antileishmanial activity of the peptidomimetic PQ deriv-
ative 3c was confirmed in this assay, as this compound was found
to be more effective than PQ at eliminating intramacrophagic L.
infantum (Table 3). Conversely, the dipeptide derivative 4c had no
effect on the elimination of intramacrophagic L. infantum amas-
tigotes (Table 3). As shown in Table 4, among the organometallic
derivatives, compound 5 showed no activity against amastigotes,
while the activity of compound 8was confirmed on this intramac-
rophagic form of the parasite (Table 4). Surprisingly, compound
7a also showed potent activity against amastigotes, revealing an
efficacy of 40 M, which is comparable to that of miltefosine
(compound 12), at 20 M (Table 4). Due to its high toxicity to-
wardmacrophages (Table 2 and Fig. 4C), miltefosine (compound
12) could not be used at concentrations higher than 20 M in
these assays. Lastly, both compounds 3c (Fig. 4E and Table 1) and
7a (Fig. 4F and Table 2) caused no significant toxicity toward
macrophages, in contrast to reference drugs 11 and 12 (Fig. 4B and
C and Tables 1 and 2). Reference drugs 11 (60 M) and 12 (20
M) clearly decreased the confluence and altered themorphology
of infected macrophages compared to those with vehicle, whereas
compounds 1 (60 M), 3c (60 M), and 7a (80 M) did not
significantly affect any of these parameters at the highest concen-
trations tested (Fig. 4).
DISCUSSION
Chemotherapy is currently the only option for themanagement of
the life-threatening disease visceral leishmaniasis. However, the
limited number of available drugs and their serious drawbacks
reinforce the urgent need for adequate therapies (5). The ideal
drug should be nontoxic, affordable, extremely effective, and eas-
ily administered during a short period in the outpatient setting,
with no associated parasite resistance. To conform to these crite-
ria, the rational modification of known antiparasitic molecules
such as PQ is a valuable strategy. The modification of the PQ
scaffold has already led to the discovery of new 8AQ with potent
antileishmanial activities, such as NPC1161B (24), tafenoquine
(44), and sitamaquine (25). However, the first two drugs have no
applicability in the clinical setting at present, and the latter has
been correlated with adverse side effects (10, 14, 34, 42). This
highlights the importance for the continuous design of new prim-
aquine-derived compounds as antileishmanial agents.
Structuralmodifications that involve the inclusion of imidazo-
lidin-4-one (peptidomimetics; compound 3) and ferrocene (or-
ganometallics; compounds 5 to 10) moieties into PQ improve its
activity against Plasmodium and Pneumocystis and/or its safety
(19, 20, 36, 40). The results disclosed in this article show that the
peptidomimetic 3c and organometallic 7a derivatives of PQ are
more effective than the parent drug at eliminating intramac-
rophagic amastigotes of L. infantum and show decreased toxicity
TABLE 3 Activities of PQ (1), 3c, 4c, and sitamaquine (11) against
intramacrophagic L. infantum
Compound
Concentration
(M)
Mean no. of
amastigotes/100
macrophages SD
(24 h)
% Reduction
in amastigotes
Vehicle 313.0 18.3
1 60 221.4 29.5 29.3
30 235.0 53.7 24.9
3c 60 7.3 1.8 97.7a
30 168.5 35.9 46.2a
4c 60 322.3 57.1 3.0
30 320.5 54.4 2.4
11 60 8.7 6.9 97.2a
30 84.1 27.1 73.1a
a P 0.001.
TABLE 4 Activities of PQ (1), 5, 7a, 8, and miltefosine (12) against
intramacrophagic L. infantum
Compound
Concentration
(M)
Mean no. of
amastigotes/100
macrophages SD
(72 h)
% Reduction
in amastigotes
Vehicle 135.8 27.5
1 80 10.6 5.1 92.2b
40 66.8 23.6 50.8a
5 80 127.8 33.5 5.9
40 99.0 32.2 27.1
7a 80 3.7 1.1 97.3b
40 5.3 1.7 96.1b
8 80 29.0 5.4 78.6b
40 30.5 3.3 77.6b
12 20 5.0 1.0 96.3b
a P 0.05.
b P 0.001.
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and similar activity compared to those of sitamaquine and milte-
fosine.
We tested 5 peptidomimetic and 9 dipeptidic derivatives of PQ
for activity against L. infantum promastigotes. Among these, com-
pounds 3c and 4c were the most active, with IC50s close to that of
PQ (compound 1). It is remarkable that compounds 3c and 4c are
closely related, as compound 3c is the imidazolidin-4-one pep-
tidomimetic surrogate of PQ’s dipeptide derivative 4c. This is
hardly coincidental and shows that the valine residue common to
the two is beneficial for in vitro antileishmanial activity against
promastigotes. Interestingly, when the compoundswere tested for
antileishmanial activity inside macrophages, compound 3c was
muchmore active than compound 4c. This is not surprising, since
compound 4c is more susceptible than compound 3c to proteo-
lytic degradation (37), which could be aggravated by the fact that
protease activity is increased in Leishmania-infectedmacrophages
(27). Proteolytic degradation would cause cleavage of the dipep-
tide moiety in compound 4c, leading to PQ release. However, if
this were the case, compound 4c would be expected to display an
activity similar to that of the parent drug, which did not occur.
Another possible explanation for the discrepant behaviors of com-
pounds 1, 3c, and 4c against either promastigotes or intracellular
amastigotes could be the fact that the macrophage metabolizes
compound 3c, but not compound 1 or 4c, to originate a com-
pound which is more toxic to L. infantum. This lack of activity of
compound 4cmay also be due to the action of amacrophage efflux
pump able to recognize dipeptide substrates, e.g., amultisubstrate
transporter from the ubiquitous ATP-binding cassette (ABC) su-
perfamily (4) or peptide/histidine transporters PHT1 and PHT2,
which are expressed in macrophages (22). It is likely that such
transporters would not recognize the peptidomimetic imidazoli-
din-4-one moiety in compound 3c. The most remarkable finding
on compound 3c, however, is the fact that this compound was as
potent as sitamaquine (compound 11) at the highest concentra-
tion tested (60 M) (Table 3), with the further advantage that
compound 3c was not cytotoxic at this concentration, whereas
sitamaquine was (Table 1; Fig. 4). Though sitamaquine (com-
pound 11) performed better than compound 3c at the lowest con-
centration tested (30 M), its high toxicity hampers its applica-
tion in clinics, which urges the discovery of safer antileishmanial
leads such as compound3c.Given this situation,we have begun an
evaluation of the efficacy of compound 3c in amousemodel ofVL.
Preliminary data indicate that low doses (116.5 nmol/mouse/day
for 21 days) of compound 3c are as effective as PQ (compound 1)
at reducing hepatic parasite loads (51.6% versus 41.8%) (data not
shown), with no evidence of negative side effects. Moreover, we
have experimentally confirmed that peptidomimetic derivatives
of PQ are less prone than PQ (compound 1) to undergometabolic
conversionmediated by rat liver enzymes (37). Thus, our peptido-
mimetic derivatives display higher in vivo antileishmanial activity,
lower toxicity, and higher stability than those of PQ.
This study allowed us to draw some conclusions regarding
structure-activity relationships. -Ramification of the amino acid
(Xaa) residue may have a role in antimicrobial activity, as all PQ
derivatives which displayed IC50s of 35 M bore a -ramified
Xaa residue (Table 1). It is possible that this particular feature
favors uptake by L. infantum parasites,mediated by specific amino
acid permeases or transmembrane peptide transporters (28) par-
allel to, e.g., the Arg-specific transporter previously reported for L.
donovani (9). Curiously, enhanced activity and uptake when
-ramified amino acids were present were previously described by
us, though with other compounds and pathogens (30, 31). Al-
though the most active compounds had high lipophilicity, we
found no direct correlation between this parameter and antipar-
asitic activity (Table 1). Other structural features in Xaa do not
seem to have any particular effect on a compound’s activity
against L. infantum.
Concerning the Fc derivatives of PQ, i.e., compounds 5 to 10
(Fig. 2), the results obtained on promastigotes (Table 2) were very
variable, reflecting the high structural diversity of these organo-
metallic compounds. Series 7a to h, in which PQ is linked to Fc
through a variable amino acid spacer, was generally not very
promising, while the removal of the amino acid spacer between
PQ and Fc, giving compound 5, led to a substantial increase in
activity. Also somewhat surprisingwas the fact that compound 10,
the most promising antimalarial compound (19), was inactive
against L. infantum promastigotes. Interestingly, compound 6,
which has the same hexylferrocene moiety as that in compound
FIG4 Micrographs of L. infantum-infected bonemarrow-derivedmacrophages exposed to vehicle (A), compound 11 at 60M(B), compound 12 at 20M(C),
compound 1 at 60 M (D), compound 3c at 60 M (E), or compound 7a at 80 M (F). Bars, 50 m.
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10, but linked to the PQ’s aliphatic amine group rather than di-
rectly bound to the aryl-amine group in 8-amino-6-methoxy-
quinoline (the heteroaromatic core of PQ), appeared remarkably
active against promastigotes, beingmore potent than both sitama-
quine (compound 11) and miltefosine (compound 12). The sec-
ondmost active compound againstL. infantumpromastigoteswas
compound 8, with an activity comparable to that of miltefosine
(compound 12). This is an interesting finding, as compound 8
includes both structural modifications pursued by our group over
the past few years in order to improve PQ’s therapeutic properties
(2, 19, 20, 40): it encompasses an imidazolidin-4-one and an Fc
moiety, i.e., it can be seen as an organometallic surrogate of pep-
tidomimetic compound 3 (Fig. 1).
Since the intramacrophagic amastigote form of Leishmania is
the most biologically relevant form, the most promising organo-
metallic PQ derivatives were also tested in this model. Unfortu-
nately, compound 6, which showed the highest activity against
promastigotes, revealed a high toxicity toward bone marrow-de-
rived macrophages, which excluded it from further studies. The
CC50 on macrophages was about 7 M, in agreement with the
cytotoxicity previously displayed on Huh-7 human hepatoma
cells (19). In contrast, compounds 5 and 8 (similar to the peptido-
mimetics of the 3 and 4 series tested previously) had very low
cytotoxicity and were selected for subsequent analysis on intra-
macrophagic amastigotes. Compound 7a, though inactive against
promastigotes, was also used further for such studies, as it is rep-
resentative of the noncytotoxic (Table 2) acyclic precursor of
compound 8. In fact, compounds 5, 7a, and 8 can be seen as
sequential analogues of each other, i.e., compound 7a is an ana-
logue of compound 5 in which the simplest amino acid (glycine)
has been introduced as a spacer between PQ and the Fc moiety,
and in turn, compound 8 is a derivative of compound 7a in which
an additional cyclization step has introduced an imidazolidin-4-
one ring. While compound 5 lost its activity inside macrophages,
compound 8 revealed a significant activity in this setting. Yet the
most striking observation was that compound 7a had potent ac-
tivity against amastigotes that was not far from that of miltefosine
(compound 12) (Table 4). Thus, in contrast to what was observed
with the peptidomimetic series, the presence of an imidazolidin-
4-one ring was not necessary for intramacrophagic activity in the
case of the organometallic derivatives. Eventually, the joining of
the constrained cyclic imidazolidin-4-one motif with the bicyclic
ferrocene moiety in compound 8 represents a structure too large
or too stiff to easily enter the macrophage and/or the amastigote.
By removing the imidazolidin-4-one ring, as in compound 7a,
such a problemmight beminimized or eliminated, explaining the
higher activity of compound 7a than that of compound 8. Another
clear fact is the key role of the amino acid residue: compound 7a
differs from compound 5 only in the fact that the latter is missing
the glycine residue present in the former, yet this difference was
enough to remove antileishmanial activity for compound 5. Cu-
riously, both compounds 7a and 5 were previously found to be
inactive either against blood-stage Plasmodium or as malaria
transmission-blocking agents, while presenting very good activity
against liver-stagemalaria parasites (19, 20). This suggests a stage-
specific antiparasitic activity, which might deserve further inves-
tigation in the future. Our results also clearly show that the assess-
ment of potential antileishmanial drugs should be performed at
the intramacrophagic amastigote stage, not the promastigote
stage, of Leishmania parasites.
The mechanisms of antileishmanial activity are not known for
most of the drugs available. In the case of sitamaquine, it is known
that the weakly basic and lipophilic characteristics are key factors
for crossing parasite membranes (8, 11). This agrees with the fact
that compound 3c, being the most active peptidomimetic deriva-
tive of PQ, is also themost lipophilic of the series 3 compounds. It
was also proposed, but subsequently questioned (17), that sitama-
quine is targeted to the parasite’s acidocalcisomes, which are
acidic vesicles where accumulation of weak bases such as sitama-
quine would be favored. One thing is certain and common to
observations with other 8AQ drugs, such as PQ (39): sitamaquine
causes swelling and impairs the function of parasitic mitochon-
dria, possibly affecting the electron transport chain and favoring
the generation of reactive oxygen species (ROS), which are prob-
ably related to its high antileishmanial activity (32). In this con-
nection,metallocene derivatives of PQ such as compounds 5 to 10
may also prove useful against Leishmania, as the ferrocene moiety
is known to undergo a Fenton-like redox reaction leading to
highly reactive oxygen species that both are pernicious for mem-
brane-unsaturated fatty acids and promote chain reactions
through peroxidation products (7, 19). Moreover, several reports
point to the pivotal role of iron, which is present in the Fc moiety,
in mediating drug toxicity. Iron potentiates the leishmanicidal
activity of the antimalarial drug artemisinin (33) or themetalloids
arsenic(III) and antimony(III) (21) by enhancing the generation
of ROS that consequently lead to cell death in L. donovani promas-
tigotes. Thus, strategies intended to augment the iron status of
Leishmania, such as inclusion of an Fc moiety in a drug, could
increase the sensitivity of the parasite to treatment.
Factors underlying the different activities described in this
study remain to be determined. However, it is clear that the
screening of a variety of PQ derivatives for antileishmanial activity
revealed two compounds with significant effects on the clinically
relevant intramacrophagic stage of L. infantum. These com-
pounds join together interesting (compound 3c) or highly potent
(compound 7a) activities with very low toxicity for host cells. This
makes them worthy candidates as leads for the development of
novel and safer PQ-based antileishmanials and emphasizes the
relevance of exploring the potential of PQ-based structures
against protozoan pathogens other than Plasmodium.
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